Clinical trial
Tanespimycin, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With…
NCT00047047 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00047047 |
|---|---|
| Title | Tanespimycin, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors |
| Official title | A Phase I Trial Of Gemcitabine, 17-Allylaminogeldanamycin (17-AAG) And Cisplatin In Advanced Solid Tumor Patients |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Other |
| Interventions | gemcitabine hydrochloride, tanespimycin, cisplatin, laboratory biomarker analysis |
| Enrollment | 78 |
| Start date | Aug 1, 2002 |
| Primary completion | Sep 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: